Personalized dosing for childhood arthritis: study aims to optimize etanercept
NCT ID NCT02030613
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 126 children with juvenile idiopathic arthritis to find the best dose of the drug etanercept. Researchers measured drug levels in the blood and checked how well the disease was controlled. The goal is to help doctors give each child the right amount for the best results with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etanercept
- What this could lead to
- If successful, this could help doctors personalize etanercept doses for children with juvenile arthritis, improving treatment effectiveness and reducing side effects.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Necker
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a biologic drug tame juvenile arthritis in kids?
- Simple core workouts may tame pain and fatigue in kids with arthritis
- Hidden muscle loss in young arthritis patients under the microscope
- Can a quick quiz replace gym tests for kids with chronic illness?
- Blood markers may spot Kids' lung disease earlier
- Ultrasound reveals hidden tendon problems in kids with arthritis